SRR35579816
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- OXIDATIVE_PHOSPHORYLATION+0.460
- PANCREAS_BETA_CELLS+0.380
- ANDROGEN_RESPONSE+0.370
- MYC_TARGETS_V1+0.360
- MTORC1_SIGNALING+0.340
- COAGULATION+0.310
- APICAL_SURFACE+0.260
- COMPLEMENT+0.260
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.380
- MYC_TARGETS_V2-0.320
- NOTCH_SIGNALING-0.240
- INTERFERON_ALPHA_RESPONSE-0.120
- MITOTIC_SPINDLE-0.120
- P53_PATHWAY-0.120
- KRAS_SIGNALING_DN-0.110
- MYOGENESIS-0.100
- DNA_REPAIR-0.050
- HEDGEHOG_SIGNALING+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195681 | — | — | 0.809 |
| 2 | SRR12475161 | — | — | 0.769 |
| 3 | MBCProject_1046_T1_RNA | — | C | 0.764 |
| 4 | SRR2170408 | GTEX | — | 0.757 |
| 5 | MDT-AP-0173 | Med | Medulloblastoma | 0.726 |
| 6 | GSM5359441 | — | — | 0.724 |
| 7 | SRR1313160 | — | E | 0.714 |
| 8 | 65fc5187-8157-4af4-b4a5-6f6c2eca70ca | — | — | 0.714 |
| 9 | TCGA-18-3415-01A-01R-0980-07 | — | cohortSQ2 | 0.711 |
| 10 | C3N-00574 | — | cohortA4 | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |